公开(公告)号：WO2022256257A1

公开(公告)日：2022-12-08

申请号：PCT/US2022/031349

申请日：2022-05-27

Applicant: AVOTRES, INC.

Inventor： JIANG, Hong

IPC: A61K35/17 ,  C12N5/0784 ,  A61K31/10 ,  A61K35/15 ,  A61K38/1709 ,  A61K38/38 ,  A61P37/02 ,  A61P37/04 ,  C07K14/70539 ,  C12N2501/22 ,  C12N2501/2304 ,  C12N5/0637 ,  C12N5/0639 ,  G01N33/505

Abstract: The present invention provides a composition comprising dendritic cells loaded with hHspGOsp, which dendritic cells are from a subject and have been fixed with paraformaldehyde (PFA). The subject may suffer from an autoimmune disease. Also provided are a method for preparing the composition; recombinant human cells comprising a heterologous gene encoding a fusion protein of HLA-E and hHspGOsp or B7sp, and expressing the fusion protein on the surface of the cells; a method for determining a percentage of maximum inhibition of testing the function of the HLA-E restricted CD8+ Treg cells from a subject, determining whether HLA-E restricted CD8+ Treg cells freshly isolated from a subject are defective, or determining whether defective HLA-E restricted CD8+ Treg cells from a subject are correctable; and a method for correcting defective HLA-E restricted CD8+ Treg cells, treating type 1 diabetes (T1D), or treating multiple sclerosis (MS).

公开(公告)号：WO2020259151A8

公开(公告)日：2020-12-30

申请号：PCT/CN2020/091781

申请日：2020-05-22

Applicant: 广州安捷生物医学技术有限公司

Inventor： 周超 ,  安鸿 ,  卢有德 ,  周玲 ,  杜永彪 ,  涂嘉琦 ,  尹海滨

IPC: C12N5/10 ,  C12N5/0784 ,  C12N15/866 ,  C12N15/90 ,  C07K19/00 ,  A61K35/17 ,  A61P35/00 ,  C07K14/535 ,  C07K14/70521 ,  C07K2319/02 ,  C12N15/86 ,  C12N15/907 ,  C12N2501/22 ,  C12N2501/2304 ,  C12N2501/25 ,  C12N2501/73 ,  C12N2502/1121 ,  C12N2710/14043 ,  C12N2800/105 ,  C12N5/0638 ,  C12N5/0639 ,  C12N9/16 ,  C12Y301/03002

Abstract: 提供一种CTL细胞的制备方法及其应用。该制备方法包括以下步骤：采用肿瘤抗原PAP-GM-CSF致敏的DC细胞诱导产生CTL细胞；敲除该CTL细胞的PD-1基因，得到PD-1敲除的CTL细胞。该制备方法得到的CTL细胞可用于制备治疗前列腺癌的药物，尤其是治疗PAP阳性的前列腺癌。该CTL细胞在回输体内后不会因肿瘤表达的PD-L1而引起CTL细胞衰竭和失能，从而对肿瘤细胞产生高效特异性细胞毒作用，提高其疗效并降低副作用。

公开(公告)号：WO2022269250A1

公开(公告)日：2022-12-29

申请号：PCT/GB2022/051581

申请日：2022-06-21

Applicant: ACHILLES THERAPEUTICS UK LIMITED

Inventor： NEWTON, Katy Rebecca ,  KOTSIOU, Eleni ,  ROBINSON, Joe ,  QUEZADA, Sergio ,  FRASER, Henrieta ,  THIRKELL, Sarah

IPC: C12N5/0783 ,  C12N5/0781 ,  A61K35/17 ,  A61P35/00 ,  C12N2501/2302 ,  C12N2501/2304 ,  C12N2501/2315 ,  C12N2501/2321 ,  C12N2501/24 ,  C12N2501/51 ,  C12N2501/515 ,  C12N2501/53 ,  C12N2502/1107 ,  C12N2502/1121 ,  C12N2502/115 ,  C12N5/0635 ,  C12N5/0636

Abstract: The present invention relates to a method for producing antigen-specific T cells and their use in a method for the treatment or prevention of cancer.

公开(公告)号：WO2023075623A1

公开(公告)日：2023-05-04

申请号：PCT/PT2022/050028

申请日：2022-10-26

Applicant: INEB (INSTITUTO NACIONAL DE ENGENHARIA BIOMÉDICA) ,  UNIVERSIDADE DO PORTO

Inventor： DOS SANTOS CUNHA, Carla Marisa ,  DOS SANTOS BARBER, Susana Gomes ,  MONTEIRO DA ROCHA BARBOSA, Mário Adolfo ,  DA SILVA PEREIRA, Paulo Miguel

IPC: C12N5/0786 ,  A61P19/02 ,  A61P29/00 ,  A61K35/15 ,  A61K48/00 ,  C12N2501/052 ,  C12N2501/15 ,  C12N2501/22 ,  C12N2501/2304 ,  C12N2501/2306 ,  C12N2501/231 ,  C12N2501/2313 ,  C12N2501/24 ,  C12N2501/25 ,  C12N2506/115 ,  C12N5/0645

Abstract: The present invention refers to monocytes and macrophages for use in the treatment of intravertebral disc (IVD) herniation. Furthermore, the macrophage cell phenotype which is most effective for use in a phagocytosis immunotherapy is herein disclosed. Thus, the present invention provides compositions comprising such macrophage phenotypes and a method for differentiation, polarization, and purification of the most effective macrophage phenotype, as well as its preferred form of administration. Another aspect of the present invention refers to the compositions employed in the said polarization of the most effective macrophage phenotype. Yet another aspect of the present invention refers to the compositions employed in the purification of the most effective macrophage phenotype through negative selection. The uses, compositions and methods of the present invention can be advantageously employed in a cell-based therapy primarily for use in the treatment of intervertebral disc (IVD) herniation, as well as for other clinical conditions improved by the regression of regeneration-adverse reactive tissues, such as wound and surgery- related scar tissue, fibrosis and necrosis; the said clinical condition being selected from the list further consisting of myocardial infraction, endometriosis, pulmonary asthma, hepatic cirrhosis, spinal cord injury and cartilage injury.

公开(公告)号：WO2022081839A1

公开(公告)日：2022-04-21

申请号：PCT/US2021/054975

申请日：2021-10-14

Applicant: AAVOCYTE, INC.

Inventor： CHANG, Aiquan ,  LIU, Chuanxin ,  LIU, Yong

IPC: C12N15/85 ,  A61K2039/5156 ,  A61K2039/53 ,  A61K35/17 ,  A61K39/0011 ,  A61K39/12 ,  C07K14/52 ,  C07K14/82 ,  C12N15/86 ,  C12N15/8645 ,  C12N2501/22 ,  C12N2501/2302 ,  C12N2501/2304 ,  C12N2501/2307 ,  C12N2501/25 ,  C12N2710/20022 ,  C12N2710/20034 ,  C12N2750/14134 ,  C12N2750/14143 ,  C12N2800/107 ,  C12N2830/00 ,  C12N2830/008 ,  C12N2830/15 ,  C12N2830/50 ,  C12N5/0638 ,  C12N5/0639

Abstract: The present disclosure provides rAAV vectors and rAAV virions that specifically express exogenous nucleic acid sequences in CD14+ cells. The rAAV vectors or virions are useful for specifically expressing exogenous nucleic acid sequences encoding, for example, cancer antigens, viral antigens, and/or bacterial antigens in monocytes and dendritic cells. The rAAV transduced CD14+ cells can be used as antigen presenting cells that induce antigen-specific T cell responses. The present disclosure further provides methods producing rAAV virions and methods of immunotherapy.